

# Sazan Rasul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8568946/publications.pdf>

Version: 2024-02-01

32  
papers

701  
citations

471509

17  
h-index

552781

26  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques. Journal of Nuclear Cardiology, 2022, 29, 492-502.	2.1	3
2	Assessment of left and right ventricular functional parameters using dynamic dual-tracer [13N]NH3 and [18F]FDG PET/MRI. Journal of Nuclear Cardiology, 2022, 29, 1003-1017.	2.1	6
3	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer and Prostatic Diseases, 2021, 24, 439-447.	3.9	0
4	Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1650-1657.	6.4	21
5	Diagnostic Role of PET/CT Tracers in the Detection and Localization of Tumours Responsible for Ectopic Cushing's Syndrome. Anticancer Research, 2021, 41, 2477-2484.	1.1	3
6	Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 2489.	3.7	6
7	Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5065-5065.	1.6	0
8	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. European Urology Open Science, 2021, 30, 63-66.	0.4	4
9	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Current Oncology, 2021, 28, 3692-3704.	2.2	5
10	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11C-Me-NB1. Journal of Nuclear Medicine, 2021, , jnumed.121.262427.	5.0	14
11	Data-driven, projection-based respiratory motion compensation of PET data for cardiac PET/CT and PET/MR imaging. Journal of Nuclear Cardiology, 2020, 27, 2216-2230.	2.1	25
12	Assessment of Myocardial Viability in Ischemic Heart Disease by PET/MRI: Comparison of Left Ventricular Perfusion, Hibernation, and Scar Burden. Academic Radiology, 2020, 27, 188-197.	2.5	20
13	Response assessment using [ <sup>68</sup> Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate, 2020, 80, 74-82.	2.3	49
14	Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 713-720.	6.4	46
15	In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR). Journal of Clinical Medicine, 2020, 9, 3446.	2.4	19
16	Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI. BMJ Open Diabetes Research and Care, 2020, 8, e001135.	2.8	7
17	Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA & T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, 661-667.	1.3	14
18	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. Current Urology Reports, 2019, 20, 68.	2.2	27

#	ARTICLE	IF	CITATIONS
19	Assessment of the kidney function parameters split function, mean transit time, and outflow efficiency using dynamic FDG-PET/MRI in healthy subjects. <i>European Journal of Hybrid Imaging</i> , 2019, 3, 3.	1.5	3
20	Assessment of attenuation correction for myocardial PET imaging using combined PET/MRI. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1107-1118.	2.1	42
21	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). <i>European Radiology</i> , 2018, 28, 4086-4101.	4.5	80
22	[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2159-2169.	6.4	35
23	Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects. <i>EJNMMI Research</i> , 2018, 8, 37.	2.5	24
24	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by <sup>18</sup> F-Fluoride and <sup>18</sup> F-FDG. <i>Journal of Nuclear Medicine</i> , 2017, 58, 968-974.	5.0	40
25	Similarities in trabecular hypertrophy with site-specific differences in cortical morphology between men and women with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0174664.	2.5	13
26	The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-12.	2.3	26
27	Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1503-1512.	6.4	38
28	Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus. <i>Endocrine</i> , 2012, 42, 496-505.	2.3	29
29	Diabetic Polyneuropathy Relates to Bone Metabolism and Markers of Bone Turnover in Elderly Patients With Type 2 Diabetes: Greater Effects in Male Patients. <i>Gender Medicine</i> , 2012, 9, 187-196.	1.4	29
30	Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. <i>Clinical Endocrinology</i> , 2012, 76, 499-505.	2.4	16
31	Relations of Adiponectin to Levels of Metabolic Parameters and Sexual Hormones in Elderly Type 2 Diabetic Patients. <i>Gender Medicine</i> , 2011, 8, 93-102.	1.4	13
32	Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2011, 10, 55.	6.8	41